HUMAN AFRICAN TRYPANOSOMIASIS (HAT) PLATFORM
Founded: 2005 in Kinshasa, Democratic Republic of the Congo
CHAGAS CLINICAL RESEARCH PLATFORM (CCRP)
Founded: 2009 in Uberaba, Brazil
LEISHMANIASIS EAST AFRICA PLATFORM (LEAP)
Founded: 2003 in Khartoum, Sudan
The HAT Platform is a research capacity strengthening network of clinicians, national control programme representatives, and scientists from the African countries most affected by sleeping sickness, as well as international institutions. The HAT Platform strengthens clinical trial capacities and methodologies in HAT-endemic countries so that new and promising treatments for this fatal disease can be rapidly and effectively evaluated, registered, and made available to patients.
Central African Republic Chad
The CCRP is a network of health authorities and scientists in the Americas and around the world. The CCRP aims to strengthen capacity, facilitate clinical research, expand community participation, provide a forum for technical discussions, and improve evaluation and delivery of new treatments for Chagas disease across the region.
Colombia Venezuela Mexico Guatemala Honduras
LEAP is a research capacity strengthening network of health authorities and scientists from the four African countries most affected by visceral leishmaniasis as well as international experts. LEAP aims to study, validate, and facilitate registration of improved treatment options for VL patients in the East African region. It provides capacity strengthening for treatment, evaluation, and clinical studies in the region.
Ecuador Bolivia Chile Argentina
Uganda Guinea Rep. of the Congo Angola Dem. Rep. of the Congo
Countries highlighted on the map represent Chagas disease-endemic Latin American countries with platform members. There are other CCRP members worldwide but not shown on the map.
The RedeLeish network brings together leishmaniasis experts in Latin America to increase collaboration and maximize existing resources and expertise in clinical trial methodologies as well as in case management of patients with VL and CL.
Network of Investigators and Collaborators in Leishmaniasis
DNDi is involved in the creation of informal networks of scientists and access advocates across the world, notably for filarial diseases, mycetoma, paediatric HIV, and hepatitis C, and is also part of existing research networks focusing on diseases in DNDi’s portfolio.
• R&D Portfolio